Literature DB >> 7486463

Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986.

M Triemstra1, F R Rosendaal, C Smit, H M Van der Ploeg, E Briët.   

Abstract

OBJECTIVE: To determine causes of death and mortality rates in patients with hemophilia over a period of 20 years, to assess changes in mortality, and to distinguish between hemophilia-related death and recent death induced by viral infections.
DESIGN: Cohort study of 919 patients followed from January 1986 to June 1992. Results were compared with outcomes of previous follow-up from 1973 to 1986.
SETTING: Consecutive national questionnaire surveys on hemophilia, using patient registries of the Netherlands Hemophilia Society and Dutch hemophilia centers. PATIENTS: 919 males hemophilia A or B who participated in a national questionnaire survey on hemophilia in 1985. Median duration of follow-up was 6.4 years, which yielded 5753 person-years of follow-up. The mean age at study entry was 30 years (range, 1 to 85 years). MEASUREMENTS: Standardized mortality ratios, causes of death, median life expectancy, age-adjusted relative risks associated with the type or severity of hemophilia, presence of inhibitors, prophylaxis, and human immunodeficiency virus infection.
RESULTS: 45 patients (5%) died between January 1986 and June 1992; 22.6 patients had been expected to die. Thus, the overall standardized mortality ratio was 2.0. The overall median life expectancy was 66 years for the cohort studied from 1973 to 1986 and 68 years for the cohort studied from 1986 to 1992. When deaths related to viral infection were excluded, the life expectancy almost equaled that of the general male population. Between 1986 and 1992, 1 patient died of ischemic heart disease compared with the 5.2 who were expected to die of this disease. Infection with HIV was the strongest independent predictor of death (relative risk, 27.5 [95% CI, 5.7 to 132.8]). After adjustment for HIV infection, no other hemophilia-related risk factors were associated with the risk of death.
CONCLUSIONS: The acquired immunodeficiency syndrome and hepatitis strongly influence mortality in patients with hemophilia. In the absence of viral infections, the life expectancy of patients with hemophilia would almost equal that of the general male population.

Entities:  

Mesh:

Year:  1995        PMID: 7486463     DOI: 10.7326/0003-4819-123-11-199512010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  The hemostatic balance revisited through the lessons of mankind evolution.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2008-02-19       Impact factor: 3.397

2.  Coronary atherosclerosis and cardiovascular mortality in hemophilia.

Authors:  C J Foley; L Nichols; K Jeong; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2009-10-26       Impact factor: 5.824

3.  Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A.

Authors:  M V Ragni; C G Moore
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 4.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

5.  Transfusion-transmitted infections in haemophilia patients.

Authors:  Bukurije Zhubi; Ymer Mekaj; Zana Baruti; Ilirijane Bunjaku; Mazllum Belegu
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

6.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

8.  Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review.

Authors:  Tammuella Chrisentery Singleton; Matthew Keane
Journal:  Ochsner J       Date:  2012

Review 9.  The management of hemophilia in elderly patients.

Authors:  Massimo Franchini; Annarita Tagliaferri; Pier Mannuccio Mannucci
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 10.  Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Authors:  Geir E Tjønnfjord; Pål Andre Holme
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.